PCI Opens Blocked Coronary Arteries Without Open Surgery. Here Is When a Stent Outperforms Medical Therapy.

The Scene

The following scene is drawn from the composite of patients I have cared for in the cath lab and on the hospital floor. All identifying details are changed.

It is 2:17 in the morning when the catheterization laboratory at a regional hospital in central Illinois activates for the second time that night. The patient is a 57-year-old construction foreman named Dennis, who drove himself to the emergency department from his farm in Douglas County after 45 minutes of crushing chest pressure that he described to his wife as “an elephant sitting on my sternum.” His ECG shows a 4-millimeter ST elevation in leads V1 through V4. His troponin is already three times the upper limit of normal.

Dennis has a STEMI. His left anterior descending artery is fully occluded.

Forty-two minutes from the time his ambulance arrived, he is on the cath table. The interventional cardiologist is making a 2-millimeter puncture in Dennis’s right wrist. A guidewire is threading through the arterial system toward Dennis’s heart. Dennis can see the fluoroscopy screen if he turns his head, but he has been told not to move.

The time that matters is the time between the first balloon inflation and the moment Dennis arrived in the emergency department. The ACC/AHA benchmark is 90 minutes. At centers like Carle Foundation Hospital in Urbana-Champaign, the median door-to-balloon time runs in the 50 to 60-minute range for STEMI activations.

Dennis will have a stent placed in his LAD. He will be on dual antiplatelet therapy for at least 12 months. He will leave the hospital in 48 to 72 hours. He has never had a procedure like this before and he does not yet understand what just happened.

This article explains what happened.

What It Is

Percutaneous coronary intervention (PCI) is the catheter-based restoration of blood flow through a blocked or narrowed coronary artery. “Percutaneous” means through the skin, without an open surgical incision. The term encompasses balloon angioplasty, coronary stent deployment, and related catheter-based techniques.

PCI evolved from Andreas Gruentzig’s first human balloon angioplasty in 1977 in Zurich. The initial procedure used only a balloon to compress and fracture plaque; elastic recoil and restenosis limited its durability. The introduction of bare-metal stents in the 1990s addressed elastic recoil. Drug-eluting stents (DES) in the early 2000s dramatically reduced restenosis rates.

Today, PCI refers almost exclusively to the combination of balloon pre-dilation and drug-eluting stent deployment. Bare-metal stents are rarely used except in specific circumstances (impending surgery requiring interruption of antiplatelet therapy, inability to take dual antiplatelet therapy due to high bleeding risk).

The Scale of PCI

More than 600,000 PCIs are performed annually in the United States 5 / Solid . The procedure is performed for:

• STEMI (ST-elevation myocardial infarction): Primary PCI is the standard of care when available within 90 minutes of first medical contact. Approximately 200,000 primary PCIs for STEMI are performed annually in the US.
• NSTEMI and unstable angina (ACS): 300,000 to 400,000 procedures annually for non-ST-elevation presentations.
• Stable ischemic heart disease: Elective PCI in patients with documented ischemia and suitable anatomy. This indication has been substantially reshaped by the ISCHEMIA trial data (discussed below).

Drug-Eluting Stents: The Current Platform

Contemporary drug-eluting stents consist of a metallic scaffold (cobalt-chromium alloy in most modern designs), a thin polymer coating, and an antiproliferative drug that elutes over 30 to 90 days. The drug suppresses smooth muscle cell proliferation, the cellular mechanism of in-stent restenosis.

The dominant drug classes used in DES are:

• Sirolimus (rapamycin) analogs: Everolimus (Xience, Abbott; Promus, Boston Scientific), zotarolimus (Resolute Integrity, Medtronic), sirolimus (Cypher, first-generation, now superseded).
• Paclitaxel: Used in first-generation Taxus stents; now largely replaced by limus-based platforms due to superior restenosis rates.

Second-generation DES (everolimus and zotarolimus-eluting) reduced in-stent restenosis to 5 to 8% at 1 year compared to 20 to 30% with bare-metal stents and 15 to 20% with first-generation sirolimus-eluting stents 5 / Solid .

The Mechanism

Balloon Angioplasty

The coronary guidewire (typically 0.014 inches in diameter, slightly thicker than a human hair) is advanced across the lesion. Over the guidewire, a balloon catheter is tracked to the stenosis site. Inflating the balloon to 6 to 14 atmospheres compresses the plaque against the vessel wall, fractures the fibrous cap and calcified plaque elements, and stretches the arterial media. This restores lumen caliber but does not remove plaque; it redistributes and compresses it.

Balloon inflation causes transient ischemia distal to the occlusion site, typically lasting 30 to 90 seconds per inflation. Patients may feel chest pressure or palpitations during prolonged inflations. The ischemia is relieved when the balloon deflates.

Stent Deployment

The stent is crimped onto a delivery balloon. The balloon-stent assembly is advanced to the lesion, and the balloon is inflated. The stent expands against the vessel wall, creating a rigid metallic scaffold that maintains luminal patency and prevents elastic recoil. The balloon is then deflated and withdrawn, leaving the permanently implanted stent.

Post-dilation with a non-compliant high-pressure balloon ensures full stent expansion against the vessel wall. Under-expansion is a major predictor of in-stent restenosis and stent thrombosis 5 / Solid . Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) guidance can verify adequate stent expansion; their use is associated with lower rates of major adverse cardiac events .

Drug Elution and Anti-Restenosis

Sirolimus and its analogs inhibit the mTOR pathway, blocking cell cycle progression from G1 to S phase in smooth muscle cells. This prevents the proliferative response that causes neointimal hyperplasia, the cellular filling-in of the stent lumen that produces restenosis 5 / Solid . Drug elution is largely complete within 30 to 90 days; the polymer scaffold remains permanently. Some third-generation stents use biodegradable polymers to reduce chronic inflammation 4 / Promising .

Stent Thrombosis

The metallic stent surface is thrombogenic until endothelialization is complete. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) prevents platelet aggregation on the stent struts during the critical endothelialization window. Premature DAPT discontinuation is the leading modifiable cause of stent thrombosis, which carries a 20 to 40% mortality rate when it occurs 5 / Solid .

Early stent thrombosis (within 30 days) occurs in 1 to 2% of PCI cases; late stent thrombosis (30 days to 1 year) in 0.4 to 0.6%; very late thrombosis (after 1 year) in 0.2 to 0.4% per year with contemporary DES 5 / Solid .

Fractional Flow Reserve and Physiologically Guided PCI

The anatomic severity of a stenosis on angiography correlates imperfectly with its functional significance. A 60% lesion in the proximal LAD may be hemodynamically significant; a 60% lesion in a small diagonal branch may not be. Fractional flow reserve (FFR) measures the ratio of mean distal coronary pressure to aortic pressure during maximal hyperemia (induced by adenosine). An FFR below 0.80 identifies a physiologically significant lesion; above 0.80, the lesion is unlikely to cause ischemia.

The FAME trial (Tonino PA, et al. N Engl J Med. 2009; doi:10.1056/NEJMoa0807611) enrolled 1,005 patients with multivessel CAD randomized to angiography-guided vs. FFR-guided PCI. FFR guidance reduced the rate of death, MI, or repeat revascularization at 1 year from 18.3% to 13.2% (p = 0.02) 5 / Solid . FAME-2 (De Bruyne B, et al. N Engl J Med. 2012; doi:10.1056/NEJMoa1205547) showed that FFR-guided PCI plus medical therapy reduced urgent revascularization versus medical therapy alone in patients with functionally significant lesions 5 / Solid . Current ACC/AHA guidelines give FFR-guided assessment of intermediate lesions a Class I recommendation 5 / Solid .

How It Is Used

Indications by Clinical Context

STEMI: Primary PCI is a Class I indication. The 90-minute door-to-balloon benchmark reflects that myocardium is dying at a rate that makes time the most important variable. For every 30-minute delay in reperfusion, there is an approximately 7.5% relative increase in 1-year mortality 5 / Solid . Fibrinolysis is the alternative when PCI is not available within 120 minutes.

NSTEMI/Unstable Angina: An early invasive strategy (coronary angiography within 24 hours of admission) is Class I for high-risk features: increased troponin, dynamic ST changes, hemodynamic instability, GRACE score above 140. For lower-risk NSTEMI, initial conservative management is appropriate, with invasive assessment within 48 to 72 hours 5 / Solid .

Stable Ischemic Heart Disease: This is the most contested indication. The ISCHEMIA trial definitively changed practice here (see Evidence section). Elective PCI for stable angina is appropriate when symptoms are not controlled with guideline-directed medical therapy (Class I), or when there is significant ischemia in a large territory on non-invasive testing (Class IIa). It is not indicated solely for prognostic benefit in stable patients who are medically controlled 5 / Solid .

The Pre-PCI Workup

For elective PCI:

• Dual antiplatelet therapy loading (aspirin 325 mg; ticagrelor 180 mg loading dose is typical in most ACS protocols; clopidogrel 600 mg for elective cases).
• Anticoagulation during the procedure: unfractionated heparin (weight-based dosing targeting ACT 250-350 seconds), bivalirudin (alternative, reduces bleeding), or enoxaparin.
• Creatinine and eGFR.
• Hemoglobin (anemia worsens ischemic tolerance and increases bleeding risk).
• INR if on warfarin.
• Platelet count.

Anatomical Complexity Scoring

The SYNTAX score quantifies coronary anatomy complexity based on the number, location, and characteristics of coronary lesions. High SYNTAX score (above 32) identifies patients who have better outcomes with CABG than with PCI (discussed further in the CABG article). Intermediate score (23 to 32) represents genuine clinical equipoise. Low score (below 22) indicates equivalent outcomes between PCI and CABG in most cases 5 / Solid .

Geographic Access in Central Illinois

PCI capability requires a catheterization laboratory with interventional cardiology staffing, an emergency cardiac surgery program on-site or within 30 minutes, and a 24/7 activation protocol. In central Illinois, Carle Foundation Hospital maintains this capability. For rural patients in areas without PCI-capable hospitals, transfer protocols define the workflow: transfer to the nearest PCI center within 90 minutes of first medical contact, or administer fibrinolytic therapy if transfer time exceeds this threshold. Illinois has a statewide STEMI system designed to minimize transfer delays; outcomes data from the Illinois SIREN registry show median door-to-balloon times for transferred STEMI patients of approximately 100 minutes 4 / Promising .

The Evidence

COURAGE Trial: PCI vs. Medical Therapy in Stable CAD

COURAGE (Boden WE, et al. N Engl J Med. 2007; doi:10.1056/NEJMoa070829) enrolled 2,287 patients with stable angina and at least one epicardial coronary stenosis of 70% or more. Patients were randomized to PCI plus guideline-directed medical therapy versus guideline-directed medical therapy alone. At a median follow-up of 4.6 years, there was no significant difference in the primary endpoint of death or MI (19% in PCI group vs. 18.5% in medical therapy group; HR 1.05, 95% CI 0.87 to 1.27) 5 / Solid . PCI did reduce angina frequency at 1 to 3 years, but this difference disappeared by 5 years. What COURAGE did not show: the medical therapy arm in COURAGE was very aggressively treated; less-than-guideline-directed medical therapy in real-world practice may shift the balance. The trial also predated second-generation DES, FFR guidance, and modern imaging.

ISCHEMIA Trial: The Modern Landmark

ISCHEMIA (Maron DJ, et al. N Engl J Med. 2020; doi:10.1056/NEJMoa1915922) enrolled 5,179 patients with stable ischemic heart disease and moderate-to-severe ischemia on non-invasive testing. All patients were required to have at least moderate ischemia (>10% ischemic territory on nuclear imaging, or >3 segments with stress-induced wall motion abnormality on echo). Patients were randomized to invasive strategy (coronary angiography followed by revascularization) versus initial conservative strategy (medical therapy). After 3.2 years median follow-up, the primary composite endpoint of CV death, MI, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest did not differ significantly (13.3% invasive vs. 15.5% conservative; HR 0.93, 95% CI 0.80 to 1.08) 5 / Solid .

The 7-year extended follow-up data from the ISCHEMIA trial showed a late divergence favoring the invasive group, particularly in patients with multivessel CAD and diabetes, though the overall population still did not show significant mortality benefit 4 / Promising . What ISCHEMIA did not show: patients with left main disease, EF below 35%, or recent ACS were excluded. The trial does not apply to unstable presentations or high-risk anatomy.

FAME and FAME-2: Physiology-Guided PCI

FAME (Tonino PA, et al. N Engl J Med. 2009; doi:10.1056/NEJMoa0807611): 1,005 patients with multivessel CAD randomized to angiography-guided versus FFR-guided PCI. At 1 year, death, MI, or repeat revascularization: 18.3% (angiography-guided) vs. 13.2% (FFR-guided); p = 0.02 5 / Solid . FFR guidance reduced unnecessary stenting by 37% (mean 2.7 vs. 1.9 stents per patient) without increasing event rates.

FAME-2 (De Bruyne B, et al. N Engl J Med. 2012; doi:10.1056/NEJMoa1205547): 1,220 patients with stable CAD and at least one FFR-significant lesion (FFR below 0.80) randomized to FFR-guided PCI plus medical therapy versus medical therapy alone. The trial was stopped early because urgent revascularization was 4.3x more common in the medical therapy arm (4.0% vs. 0.9% at 2 years; p < 0.001) 5 / Solid . At 5 years, the PCI advantage for the composite of death, MI, and urgent revascularization persisted (HR 0.59, 95% CI 0.48 to 0.73) 5 / Solid .

DAPT Duration: How Long?

The DAPT trial (Mauri L, et al. N Engl J Med. 2014; doi:10.1056/NEJMoa1409312) enrolled 9,961 patients who received DES and remained event-free on DAPT for 12 months, then randomized to continuing DAPT vs. aspirin alone for an additional 18 months. Continued DAPT reduced stent thrombosis (0.4% vs. 1.4%; p < 0.001) and MACE (4.3% vs. 5.9%; HR 0.71; p < 0.001) 5 / Solid . However, continued DAPT increased moderate or severe bleeding (2.5% vs. 1.6%; p = 0.001). For patients at low bleeding risk, 12 to 30 months of DAPT after DES is reasonable; for high bleeding risk, 6 months may be sufficient with contemporary polymer stents 5 / Solid 32943-1).

P2Y12 Inhibitor Choice: Ticagrelor vs. Clopidogrel

The PLATO trial (Wallentin L, et al. N Engl J Med. 2009; doi:10.1056/NEJMoa0904327) enrolled 18,624 patients with ACS randomized to ticagrelor versus clopidogrel. Ticagrelor reduced the primary endpoint of vascular death, MI, or stroke at 12 months (9.8% vs. 11.7%; HR 0.84, 95% CI 0.77 to 0.92; p < 0.001) 5 / Solid with no increase in overall major bleeding, though non-CABG bleeding was slightly higher with ticagrelor (4.5% vs. 3.8%; p = 0.03). Ticagrelor is preferred over clopidogrel for ACS patients undergoing PCI at most US centers.

TRITON-TIMI 38 (Wiviott SD, et al. N Engl J Med. 2007; doi:10.1056/NEJMoa0706482) showed prasugrel reduced CV death, MI, or stroke vs. clopidogrel in patients with ACS undergoing PCI (9.9% vs. 12.1%; HR 0.81; p < 0.001) 5 / Solid but with higher life-threatening bleeding (1.4% vs. 0.9%; p < 0.001). Prasugrel is avoided in patients older than 75 years, weight below 60 kg, or prior stroke/TIA.

Bleeding After PCI: The HORIZONS-AMI Legacy

Bleeding complications after PCI predict mortality independently of ischemic complications. HORIZONS-AMI (Stone GW, et al. N Engl J Med. 2008; doi:10.1056/NEJMoa0801579) enrolled 3,602 STEMI patients randomized to bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor. Bivalirudin reduced net adverse clinical events (9.2% vs. 12.1%; p = 0.005), driven primarily by a large reduction in major bleeding (4.9% vs. 8.3%; p < 0.001) 5 / Solid . The 30-day stent thrombosis rate was higher with bivalirudin (2.5% vs. 1.9%; p = 0.03), but this difference did not translate into a mortality excess at 1 year.

The Patient Experience

Dennis woke from the procedure with a pressure dressing on his wrist and a mild headache from the sedation. His chest pain was gone.

The cardiologist came to see him 30 minutes later and told him what was found: a 99% occlusion of the proximal LAD, now treated with a 3.0 x 28 mm drug-eluting stent. Completely open. Good flow.

What Dennis did not understand in that 8-minute conversation, and what this section covers:

What Your Cardiologist Will Not Have Time to Explain

• The stent is permanent. It will be in Dennis’s LAD for the rest of his life. The metallic scaffold does not dissolve, does not move, and cannot be removed. Over time, the vessel wall will grow over it (endothelialization). The stent itself becomes part of the artery wall.

• DAPT is not optional. Dennis will be on both aspirin and a P2Y12 inhibitor for at least 12 months. If he has a dental procedure, a colonoscopy, or an elective surgery in the next 12 months, he must tell every provider he has a coronary stent. Stopping his P2Y12 inhibitor without cardiology consultation during that window creates a real risk of stent thrombosis, which presents as a sudden, severe heart attack with 20 to 40% mortality.

• The stent did not cure his coronary artery disease. The LAD is now open. The disease that caused the blockage is still present in the vessel wall, in other vessels, and in the small vessels not visible on angiography. The stent treated a specific lesion. The underlying atherosclerosis requires lipid management, blood pressure control, smoking cessation, and antiplatelet therapy indefinitely.

• Troponin will be increased for 3 to 5 days. Even a successfully treated STEMI leaves myocardial injury markers increased. Dennis’s first post-PCI echo will likely show some wall motion abnormality in the LAD territory. Repeat echo at 4 to 6 weeks will show whether the myocardium has recovered (stunning vs. infarction).

• Chest discomfort in the weeks after PCI should be reported. Not all post-PCI chest discomfort is dangerous. Pleuritis, musculoskeletal pain from lying still during the case, and GI irritation from dual antiplatelet therapy are common. But recurrent ischemic-type chest pain at rest or with minimal exertion in the first months after stent placement warrants evaluation the same day, not “watching at home.”

Sex Differences in PCI Outcomes

Women have smaller coronary arteries on average than men, independent of body surface area 5 / Solid . Smaller vessel diameter is a predictor of in-stent restenosis even with contemporary DES, because the ratio of stent strut surface area to vessel lumen is less favorable in smaller vessels.

Women presenting with STEMI have higher in-hospital mortality than men (approximately 10% vs. 5%), attributable in part to older age at presentation, higher prevalence of diabetes and hypertension, higher rates of spontaneous coronary artery dissection as an alternative mechanism, and delays in seeking care due to atypical symptoms 5 / Solid . After adjustment for age, comorbidities, and lesion characteristics, the sex difference in mortality after PCI narrows substantially.

Decisions and Trade-Offs

PCI vs. CABG: When It Matters

For single-vessel disease and most two-vessel disease, PCI and CABG produce equivalent long-term survival, and PCI is preferred because it avoids the morbidity of open chest surgery. For left main disease and complex three-vessel disease, the data are less clear and depend heavily on SYNTAX score and patient factors.

The SYNTAX trial (Serruys PW, et al. N Engl J Med. 2009; doi:10.1056/NEJMoa0804626) enrolled 1,800 patients with three-vessel CAD or left main disease randomized to PCI vs. CABG. At 12 months, CABG was superior in the primary composite endpoint (major adverse cardiac and cerebrovascular events: 12.4% CABG vs. 17.8% PCI; p = 0.002) 5 / Solid , driven by higher repeat revascularization in the PCI arm. Patients with SYNTAX score above 32 had especially poor PCI outcomes. Stroke was more common with CABG (2.2% vs. 0.6%; p < 0.003).

For left main specifically, EXCEL (Stone GW, et al. N Engl J Med. 2016; doi:10.1056/NEJMoa1610227) and NOBLE (Makikallio T, et al. Lancet. 2016; doi:10.1016/S0140-6736(16)32052-9) showed equipoise between PCI and CABG for left main disease with low SYNTAX score at 3 to 5 years, with CABG showing late advantages in some analyses. The left main PCI vs. CABG debate is discussed in the CABG article.

The Revascularization Decision in Stable Disease After ISCHEMIA

ISCHEMIA changed the framework. For a patient with stable symptoms adequately controlled with three anti-anginal medications and moderate ischemia on nuclear imaging, elective PCI is not indicated for prognostic benefit. It may be offered for symptom relief. The patient should understand:

• PCI for stable disease reduces angina in the near term (1 to 3 years)
• PCI for stable disease does not reduce mortality or spontaneous MI at 3 to 5 years compared with guideline-directed medical therapy
• The initial risk of the procedure (0.1 to 0.5% peri-procedural MI or death for elective cases) must be weighed against the anticipated symptom benefit

A patient who is on maximal medical therapy and still limiting their life because of angina is a different candidate than a patient whose symptoms are well-controlled. The former has a legitimate reason for revascularization; the latter does not, based on current evidence.

Cost of PCI

PCI for STEMI is a covered benefit under Medicare and virtually all commercial insurance. The facility and professional fee for a single-vessel PCI typically ranges from $15,000 to $40,000 before insurance adjustments. Patient out-of-pocket costs depend on plan design; most patients with Medicare or commercial coverage pay a few hundred to a few thousand dollars. The greater financial burden is the cost of DAPT for 12 months: ticagrelor (brand Brilinta) costs $400 to $500 per month without coverage; clopidogrel is now generic at under $20 per month. Insurance coverage for ticagrelor varies, and cost remains a real barrier to adherence in uninsured and underinsured patients.

The Three Questions Every Patient Should Ask

1. “Is this lesion causing my symptoms, and have you measured the FFR or iFR to confirm it is physiologically significant?” Particularly for intermediate lesions (40 to 70%), a non-flow-limiting lesion should not be stented.

2. “Given my anatomy, am I better served by PCI or CABG? Have you discussed my case with a cardiac surgeon?” The Heart Team model (cardiology plus cardiac surgery) is the standard for complex multivessel disease; any single-operator decision on multivessel PCI without surgical input warrants scrutiny.

3. “What is my DAPT plan, and what happens if I need surgery in the next 12 months?” Every patient who receives a stent deserves a written DAPT plan and clear instructions about who to call before stopping antiplatelet therapy.

Clinical Synthesis

Dennis’s story is the version of cardiovascular disease that most people understand: sudden onset, emergency procedure, dramatic outcome. The core clinical thesis addresses the upstream version: the years before Dennis’s LAD occluded, when his LDL-C was 158 mg/dL and no one acted, when his ApoB was 130 mg/dL and was never measured, when his exercise tolerance was declining and no stress test was ordered.

PCI is essential medicine. It saves lives in STEMI. It reduces angina in stable disease. But it is a repair procedure, not a prevention procedure. The artery that Dennis’s interventional cardiologist just opened was blocked because of atherosclerosis that started accumulating in his thirties and forties. The stent addresses the acute event. It does not address the disease.

If you have had a PCI: A structured cardiovascular assessment is the appropriate next step. The Audit reviews what the post-PCI echo showed (EF, wall motion), what medical therapy is in place, what the antiplatelet plan is, whether an exercise tolerance test has been planned, and what the target LDL-C, ApoB, and blood pressure are given your anatomy. Most patients who leave the hospital after PCI receive a discharge prescription and a follow-up appointment. Few receive a structured plan for the next 5 years.

If you are deciding whether to have an elective PCI: the Signal Check gives you the context to understand your risk profile and whether non-invasive options have been exhausted before the procedure. The ISCHEMIA data matter. They mean that for a stable patient on good medical therapy, elective PCI adds symptom relief but not years to life. That is a legitimate reason to proceed if symptoms are limiting. It is not a reason to proceed if you are asymptomatic.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.